Patient Information

Celladon is conducting a Phase 2 clinical trial with MYDICAR® for patients with NYHA Class III/IV heart failure.  To see if you are eligible to participate in this ongoing clinical trial, download this patient questionnaire form and additional information to review with your physician. Read More

April 7, 2009 - Watch a video report from Fox News Nashville Reports LIVE on Tullahoma Man Treated with Celladon’s MYDICAR® at The Heart Center at Harton Regional Medical Center

Technology

Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR®, a potential breakthrough for the treatment of severe heart failure. MYDICAR is designed to restore a critical enzyme necessary for the heart to pump more efficiently. Read More

Clinical Trials

MYDICAR® is currently in Phase 1/2 clinical testing to investigate safety and biological effects of restoring specific enzyme activity. Replacing the enzyme may restore function and reverse heart failure. The Phase 1 portion is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. This study is currently enrolling patients with advanced heart failure at 15 leading cardiology medical centers across the U.S. Read More